These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2351631)

  • 21. In vitro activity of beta-lactam drugs and sulbactam against Chlamydia trachomatis.
    Segreti J; Kapell KS; Trenholme GM
    Diagn Microbiol Infect Dis; 1992; 15(4):371-3. PubMed ID: 1611854
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro comparison of cefoperazone/sulbactam with selected antimicrobials against 300 bacteroides isolates. Inhibitory activity and time-kill kinetic studies.
    Gelfand MS; Grogan JT; Haas MJ
    Diagn Microbiol Infect Dis; 1989; 12(5):421-8. PubMed ID: 2612130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Error rates in cefoperazone and cefoperazone-sulbactam disk tests with Enterobacteriaceae and Pseudomonas aeruginosa.
    Hardy DJ; Barry AL; Fuchs PC; Gerlach EH; McLaughlin JC; Pfaller MA
    Eur J Clin Microbiol Infect Dis; 1992 Oct; 11(10):926-30. PubMed ID: 1486889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. II. In vitro combined effects of sulbactam/cefoperazone with imipenem/cilastatin, cefuzonam, flomoxef, amikacin or tobramycin].
    Kouda M; Kumagai I; Kobayashi J; Sugai R; Matsuzaki H
    Jpn J Antibiot; 1991 Feb; 44(2):130-9. PubMed ID: 2041154
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparative in vitro activity of cefoperazone and various combinations of cefoperazone/sulbactam.
    Knapp CC; Sierra-Madero J; Washington JA
    Diagn Microbiol Infect Dis; 1990; 13(1):45-9. PubMed ID: 2331849
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synergy of gatifloxacin with cefoperazone and cefoperazone-sulbactam against resistant strains of Pseudomonas aeruginosa.
    Sivagurunathan N; Krishnan S; Rao JV; Nagappa AN; Subrahmanyam VM; Vanathi BM
    J Med Microbiol; 2008 Dec; 57(Pt 12):1514-1517. PubMed ID: 19018022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of beta-lactamase inhibitors on the potency of their companion drug with organisms possessing class I enzymes.
    Cavalieri SJ; Sanders CC; New C
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1343-7. PubMed ID: 1929291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multicentre study on antibiotic susceptibilities of anaerobic bacteria to cefoperazone-sulbactam and other antimicrobial agents.
    Clark RB; Bartelt MA; Chan EL; Dalton HP
    J Antimicrob Chemother; 1992 Jan; 29(1):57-67. PubMed ID: 1737725
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of tigecycline in combination with cefoperazone-sulbactam against multidrug-resistant Acinetobacter baumannii.
    Liu B; Bai Y; Liu Y; Di X; Zhang X; Wang R; Wang J
    J Chemother; 2015 Oct; 27(5):271-6. PubMed ID: 25068186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Antibiotic activity and synergism of ceftazidime and netilmicin against gram-negative pathogenic bacteria].
    Baumgärtner M; Müller HP; Wundt W
    Arzneimittelforschung; 1983; 33(12):1615-9. PubMed ID: 6320836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination.
    Jones RN; Barry AL; Packer RR; Gregory WW; Thornsberry C
    J Clin Microbiol; 1987 Sep; 25(9):1725-9. PubMed ID: 3498740
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kinetics of antimicrobial activity of aztreonam/clavulanic acid (2:1) against Xanthomonas maltophilia.
    García-Rodríguez JA; García Sánchez JE; Muñoz Bellido JL; García García MI; García Sánchez E
    J Antimicrob Chemother; 1991 Apr; 27(4):552-4. PubMed ID: 1856134
    [No Abstract]   [Full Text] [Related]  

  • 34. [Errors of the agar diffusion method to predict Escherichia coli's susceptibility to ampicillin-sulbactam and amoxicillin-clavulanic acid].
    Villar HE; Jugo MB; Fernández-Lausi A; Farinati AE
    Enferm Infecc Microbiol Clin; 1996 May; 14(5):308-10. PubMed ID: 8744371
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activity of cefoperazone-sulbactam combination against gram negative bacilli.
    Poudyal N; Gyawali N; Gurung R; Bhattarai NR; Baral R; Khanal B; Shrestha S; Amatya R; Bhattacharya SK
    Nepal Med Coll J; 2012 Mar; 14(1):5-8. PubMed ID: 23441486
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests.
    Jones RN; Barry AL; Thornsberry C; Wilson HW
    Am J Clin Pathol; 1985 Oct; 84(4):496-504. PubMed ID: 2994461
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria.
    Mohanty S; Singhal R; Sood S; Dhawan B; Das BK; Kapil A
    Indian J Med Res; 2005 Nov; 122(5):425-8. PubMed ID: 16456257
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro susceptibility of Campylobacter jejuni to 27 antimicrobial agents and various combinations of beta-lactams with clavulanic acid or sulbactam.
    Van der Auwera P; Scorneaux B
    Antimicrob Agents Chemother; 1985 Jul; 28(1):37-40. PubMed ID: 2994557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Synergistic effect of new beta-lactam antibiotics, clavulanic acid and dibekacin on pathogenic microorganisms].
    Jastalska D; Lupicki W; Zapaśnik M; Pajchel G; Chojnowski W
    Pol Tyg Lek; 1984 Oct; 39(43):1415-8. PubMed ID: 6440130
    [No Abstract]   [Full Text] [Related]  

  • 40. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.